Oppenheimer Names Cepheid on December's Top Ideas

A report from Oppenheimer reiterates its Outperform rating on Cepheid (NASDAQ: CPHD).

The report states, “Cepheid is a pure play molecular diagnostic company with a pioneering technology platform. The company provides a fully integrated, random access, scalable, molecular diagnostic solution for a variety of disease states. The GeneXpert platform has a very easy-to-use interface and can produce results in as little as one hour with approximately two minutes of prep time by the technician.”

CPHD closed Friday at $31.48.